Breaking News

Vital Therapies Expands Executive Team

September 6, 2013

Swanson, Henry, Loewen, and Murawski take on financial, clinical, regulatory, and manufacturing roles

Michael Swanson has been appointed chief financial officer and treasurer of Vital Therapies, Inc. (VTI). He has more than 20 years of experience in senior financial positions in public and private life sciences companies. Mr. Swanson has served as chief financial officer at Amira Pharmaceuticals, Prometheus Labs, and Advanced Tissue Sciences. He also served as director of finance of the Fisher Scientific Group, and its parent, The Henley Group.    
Andrew Henry has been named vice president of clinical operations, responsible for global implementation of the company's clinical program. Mr. Henry has 23 years of experience managing clinical trials in life science companies with roles at Schering-Plough Oncology, Novartis Oncology and MedImmune, the biologics division of Astra Zeneca. Most recently, he served as senior director of global clinical operational strategy, and as senior director of clinical trial management at MedImmune. 
Andrea Loewen has been appointed vice president of regulatory affairs and quality, responsible for building out the company's quality and regulatory systems to ensure compliance and continued development of late-stage regulatory strategies. Ms. Loewen has 24 years of experience in regulatory and quality management roles, including positions at Baxter Healthcare, Biogen Idec, and Shire Pharmaceuticals. Most recently, she served as the head of regulatory affairs for the Shire Regenerative Medicine business, where she was responsible for global regulatory oversight of licensed and development stage combination biologic and medical device products. 
Richard Murawski was appointed vice president of manufacturing, responsible for manufacturing of the cellular therapy and device components of the company’s extracorporeal liver assist device, ELAD. He has four decades of experience in pharmaceutical manufacturing, including significant experience in cellular therapy manufacturing and engineering at Dendreon. His prior manufacturing roles were at Cytogen, Baxter Healthcare and Favrille, where he has developed and overseen international manufacturing organizations and directed the design, construction, validation, regulatory approval, and start up of multiple international biotech manufacturing facilities.
Terry Winters, Ph.D., the company's chief executive officer and co-chairman, said, "Each of our new members holds a wealth of experience in their respective fields. We are fortunate to have a team of this exceptional caliber to oversee our recently-initiated Phase III program, anticipated regulatory filings and transition to commercialization."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016